Efficacy And Safety Of Budesonide Oral Suspension In A Pediatric Population: Pooled Data From A Phase 2 And Phase 3 Trial In Patients With Eosinophilic Esophagitis - 01/02/21
Doi : 10.1016/j.jaci.2020.12.348
Sandeep Gupta 1, Vincent Mukkada 2, Evan Dellon, MD 3, Benjamin Gold, MD 4, Margaret Collins, MD 5, David Katzka, MD 6, Gary Falk, MD, MS 7, Lan. Lan, PhD 8, Nirav Desai, MD 8, James Williams, MD 8, Ikuo Hirano, MD 9
1 Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health
2 Cincinnati Children's Hospital Medical Center
3 University of North Carolina at Chapel Hill
4 Children's Center for Digestive Healthcare, LLC, GI Care for Kids
5 Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine
6 Mayo Clinic
7 University of Pennsylvania Perelman School of Medicine
8 Shire, a Takeda company
9 Northwestern University Feinberg School of Medicine
291
Le texte complet de cet article est disponible en PDF.Plan
© 2020
Publié par Elsevier Masson SAS.
Vol 147 - N° 2S
P. AB91 - février 2021 Retour au numéro
Article précédent
- Dupilumab Improves Health-Related Quality of Life (HRQoL) and Reduces Symptom Burden in Patients with Eosinophilic Esophagitis (EoE): Results From Part A of a Randomized, Placebo-Controlled Three-Part Phase 3 Study
- Evan Dellon, Marc Rothenberg, Ikuo Hirano, Mirna Chehade, Albert J. Bredenoord, Jonathan Spergel, Qiong Zhao, Bethany Beazley, Isabelle Guillemin, Leda Mannent, Elizabeth Laws, Nikhil Amin, Brad Shumel, Jennifer Maloney, Siddhesh Kamat
- Endotype and Phenotype Relationships in Children With Eosinophilic Esophagitis Treated With Diet Elimination
- Melissa Watts, Rethavathi Janarthanam, Ming Wang, Kaitlin Keeley, Joshua Wechsler
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?